Company profile
HERON THERAPEUTICS, INC. /DE/
NASDAQ:HRTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| APREPITANT | approved | — | 24 | approved |
| Bupivacaine | approved | — | 18 | approved |
| GRANISETRON | approved | — | 3 | approved |
| Meloxicam | approved | — | 3 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (25)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06109428 | phase4 | completed | 2021-10-12 | 2022-03-29 | Heron Therapeutics | A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE |
| NCT06109415 | phase4 | completed | 2021-10-20 | 2022-07-18 | Heron Therapeutics | A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. |
| NCT05109312 | phase4 | unknown | 2021-10-12 | 2024-06-01 | Heron Therapeutics | A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401. |
| NCT02106494 | phase3 | completed | 2014-03-01 | 2015-05-01 | Heron Therapeutics | A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC |
| NCT00343460 | phase3 | completed | 2006-06-01 | 2008-09-01 | Heron Therapeutics | APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer |
FDA applications (4)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 022445 | NDA | HERON THERAPEUTICS INC | ||||
Loading… | ||||||
| NDA 209296 | NDA | HERON THERAPEUTICS INC | ||||
Loading… | ||||||
| NDA 211988 | NDA | HERON THERAPEUTICS INC | ||||
Loading… | ||||||
| NDA 216457 | NDA | HERON THERAPEUTICS INC | ||||
Loading… | ||||||